TBXAS1 and atherosclerosis: In the last decades, numerous reports have suggested that TP receptor antagonism (with sulotroban or terutroban) or direct inhibition of thromboxane synthase (TxAS) (with furegrelate) can not only have antiplatelet effects but also impact endothelial dysfunction as well as the inflammatory component of atherosclerosis [8–11].